Equity compensation at pre-IPO biotechs operates under fundamentally different rules than equity at technology companies, and most life sciences professionals who join clinical-stage companies do not fully understand those rules until they’re already vesting. The binary nature of clinical trial outcomes, the extended pre-revenue timeline, the dilution from multiple financing rounds, and the milestone-driven valuation changes all create an equity calculus that is genuinely unlike anything in SaaS, fintech, or enterprise software. This piece covers what we’ve learned from placing over 200 senior professionals into pre-IPO biotech companies over the past four years.
The core insight is straightforward: biotech equity is not a compensation component; it is a bet on clinical success. The expected value of a 0.5% fully diluted equity grant at a Series B oncology company depends almost entirely on whether the lead asset achieves its primary endpoint in Phase II. All the standard equity negotiation advice — strike price, vesting schedule, dilution protection — is secondary to the probability that the underlying science works. Professionals who treat biotech equity as a reliable compensation component consistently overestimate their total earnings; professionals who treat it as a call option on clinical success make better career decisions.
How company stage affects equity value
The relationship between company stage and equity grant size is inverse in biotech: earlier-stage companies offer larger percentage grants with lower expected values, while later-stage companies offer smaller percentage grants with higher expected values. The specific ranges from our 2024-2025 placement data:
- Seed / Series A (preclinical): VP-level grants of 0.8% to 1.5% fully diluted. 409A valuations typically $0.20-$1.50 per share. Probability of meaningful exit: 8-15%
- Series B (Phase I/early Phase II): VP-level grants of 0.4% to 0.8% fully diluted. 409A valuations typically $2-$8 per share. Probability of meaningful exit: 15-25%
- Series C/D (Phase II/Phase III): VP-level grants of 0.15% to 0.4% fully diluted. 409A valuations typically $8-$25 per share. Probability of meaningful exit: 25-45%
- Pre-IPO (Phase III data in hand): VP-level grants of 0.05% to 0.15% fully diluted. 409A valuations approaching IPO price. Probability of meaningful exit: 50-70%
The critical variable that most candidates underestimate is dilution. A 0.8% fully diluted grant at a Series B company will be diluted by every subsequent financing round. If the company raises a Series C at $150M post-money (diluting existing shares by 25%) and then a Series D at $400M post-money (diluting by another 20%), the original 0.8% becomes approximately 0.48% — a 40% reduction before any value is realized. Anti-dilution provisions in executive agreements are rare at biotech companies below $500M in market capitalization; professionals who negotiate them have substantial leverage, but most don’t ask.
Clinical readouts and equity volatility
The single most important driver of biotech equity value is the clinical trial readout. A positive Phase II readout for a first-in-class oncology drug can increase a company’s valuation by 200% to 500% overnight. A negative readout can destroy 60% to 90% of the company’s value in a single trading session (or, for private companies, trigger a down round that devastates existing equity holders). No comparable event exists in technology companies, where valuation changes are driven by revenue growth patterns rather than single binary events.
For equity negotiation purposes, the proximity of the next clinical readout is a critical variable. Joining a company 18 months before a pivotal readout means accepting maximum uncertainty about whether your equity will be worth anything. Joining after a positive readout means paying a much higher entry price (reflected in the 409A valuation and therefore your strike price) but having substantially more confidence in the equity’s value.
Our advice to candidates: request the clinical development timeline as part of your diligence. Understand when the next data readout is expected, what the primary and secondary endpoints are, and what the statistical powering assumptions are. A well-informed assessment of clinical probability should be part of your compensation evaluation, not an afterthought. The company’s investor presentations and ClinicalTrials.gov listings are public; use them.
Milestone-based vesting structures
Standard four-year time-based vesting with a one-year cliff is common at biotech companies, but an increasing number of clinical-stage biotechs are incorporating milestone-based vesting components that tie equity vesting to specific clinical or regulatory events. In our 2024 data, approximately 28% of VP-level and above biotech offers included some form of milestone-based vesting, up from 12% in 2020.
Common milestone vesting structures include:
- IND filing acceleration: 25% of the grant vests upon successful IND filing, with the remainder on standard time-based vesting
- Phase transition bonuses: Additional equity grants (typically 0.1% to 0.3% fully diluted) triggered by successful Phase I-to-Phase II or Phase II-to-Phase III transitions
- Regulatory milestone grants: Equity bonuses tied to NDA/BLA submission and FDA approval, typically structured as new grants rather than acceleration of existing vesting
- Double-trigger acceleration: Full acceleration on change of control (acquisition) combined with involuntary termination within 12 months of the transaction
The negotiation priority for most biotech executives should be double-trigger acceleration on change of control. M&A is the most common liquidity event for clinical-stage biotechs (more common than IPO), and without double-trigger protection, an acquisition can result in the termination of the executive with only partially vested equity. In our experience, double-trigger acceleration is negotiable at approximately 75% of clinical-stage biotechs and should be requested in every offer negotiation.
409A valuations in biotech
The 409A valuation is the IRS-determined fair market value of common stock at a private company, and it directly determines the strike price of stock options granted to employees. At biotech companies, 409A valuations have specific characteristics that candidates should understand:
409A valuations at biotech companies are updated irregularly and can change dramatically. A typical cadence is annually, but a new financing round, a clinical data readout, or a material partnership agreement will trigger an interim update. The practical implication: the timing of your grant relative to the most recent 409A update materially affects your strike price. A grant issued one month before a positive Phase II readout will have a much lower strike price than a grant issued one month after. This timing effect can represent hundreds of thousands of dollars in eventual value.
The discount between 409A valuation and preferred stock price is typically larger at biotech companies than at technology companies, reflecting the higher risk and binary outcomes. At a Series B biotech, the 409A valuation for common stock might be 25% to 40% of the preferred stock price paid by investors. At a Series B SaaS company, the discount is typically 15% to 25%. The larger discount works in the candidate’s favor, providing a lower strike price and more upside potential.
Ask for the most recent 409A valuation report during your offer evaluation. Companies are not required to share it, but most will provide the per-share common stock value and the date of the most recent valuation. This information, combined with your grant size and the fully diluted share count, allows you to calculate your ownership percentage and assess the implied company valuation at which your options would be "in the money."
Real equity outcome examples
To illustrate the range of actual outcomes, three anonymized scenarios from our placement history:
Scenario A: The home run. VP of Clinical Development joined a Series B oncology biotech in 2020 with 0.6% fully diluted at a 409A strike of $1.80/share. The company’s Phase II data exceeded expectations; it IPO’d in 2022 at $18/share and traded at $34/share 12 months post-IPO. After dilution from the IPO and a follow-on offering, the VP’s stake was approximately 0.38% of the public float. Pre-tax value at peak: approximately $8.2 million. The VP exercised and sold over a 6-month window, realizing approximately $6.8 million after taxes and transaction costs.
Scenario B: The moderate outcome. Director of Regulatory Affairs joined a Series C rare-disease biotech in 2021 with 0.25% fully diluted at a 409A strike of $5.20/share. The company was acquired in 2023 for $24/share plus a $4/share CVR (contingent value right) tied to a European regulatory approval. After dilution, the Director’s stake was approximately 0.18%. Pre-tax value: approximately $540K from the upfront payment, plus a potential $120K from the CVR (which ultimately paid out in 2024). Net realized: approximately $480K after taxes.
Scenario C: The loss. VP of Medical Affairs joined a Series B CNS biotech in 2021 with 0.5% fully diluted at a 409A strike of $3.40/share. The company’s Phase II trial in major depressive disorder failed to meet its primary endpoint in 2023. The company’s valuation dropped 72%, triggering a restructuring that eliminated the VP’s role. The VP’s options were underwater (current valuation below strike price) and expired worthless. Total equity value realized: $0. The VP had accepted a $45K reduction in base salary relative to a competing offer in exchange for the equity upside.
The three scenarios illustrate the fundamental point: biotech equity outcomes follow a power law distribution, not a normal distribution. A small number of outcomes generate substantial wealth; the majority generate modest returns or nothing. Professionals evaluating biotech equity should calibrate their expectations accordingly and avoid treating the equity as a reliable component of their compensation.
Final thoughts
Biotech equity compensation is a genuinely different asset class from technology equity, and professionals who treat the two interchangeably make consistently poor decisions. The key principles: understand the clinical probability that underlies your equity’s value; negotiate for milestone-based vesting and double-trigger acceleration; request the 409A valuation and fully diluted share count during offer evaluation; and maintain realistic expectations about the probability distribution of outcomes.
For candidates evaluating pre-IPO biotech opportunities, the equity component should be analyzed as a risk-adjusted expected value, not as face-value compensation. A 0.5% grant at a company with a 20% probability of successful exit at $500M is worth approximately $500K in expected value — a meaningful number, but not the $2.5M that the "upside case" implies. Making career decisions based on the upside case rather than the expected value is the most common equity-related mistake we see in life sciences recruiting.
For related reading, see our analysis of CMO compensation structures where equity is the dominant variable, and our piece on counter-offers in pharma and biotech where equity retention is often the deciding factor.